Fundraising FoxSofinnova Partners — 2021 Investments
11 investments dated 2021 · listed companies and verified rows first · show all
Home Biosciences was a venture builder in Continental Europe dedicated to creating and scaling biotech companies through an asset-centric, hub-and-spoke model, working with academics and scientists on drug discovery and molecular profiling projects.
AI & Machine LearningBiotechHealthtech
David Schilansky(Co-founder & Non-executive Chairman)inMagali Richard(Co-founder)in
Co-investorsREDMILE
Clinical-stage gene therapy company developing AAV therapeutics for inherited retinal disorders.
Co-investorsLongwood FundNeva Sgr.Sixty Degree CapitalXGEN VentureAtlas VentureForbion
Borea Therapeutics develops gene therapy delivery technologies based on a proprietary AAV conjugation platform targeting neurological and genetic diseases.
BiotechDeep TechHealthtechMedical Devices
Paul Heppenstall(Scientific Co-Founder)Niccolò Bacchi(CEO)in
DMC Biotechnologies is a U.S.-based biomanufacturer that uses precision fermentation and its Dynamic Metabolic Control platform to produce bio-based specialty chemicals and ingredients, such as L-alanine and fermented inositols.
BiotechClimate TechNew MaterialsBoulder, US
Matthew Lipscomb(Director)Josh Yelen(Executive Officer)Jim Flatt(Executive Officer, Director)in
BoardJosko Bobanovic(Director)Rob van der Meij(Director)inAlastair Cooper(Director)
Co-investorsBreakthrough Energy VenturesCIBUS ENTERPRISE FUND II LPBoulder VenturesCapricorn Venture PartnersMichelin Ventures
GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.
BiotechHealthtechNewton, US
Ganesh V. Kaundinya(President & CEO)in
Co-investors5AM VenturesCatalio Capital Management, LPLifeArc VenturesRoche Venture FundSixty Degree CapitalAgent Capital+1 more
Meiogenix develops a proprietary recombination technology that targets meiotic recombination to accelerate genetic gain and variety development in crops.
AgTechBiotechDeep Tech
Ricardo Garcia de Albain
Co-investorsGenoa VenturesKurma PartnersCasdin Capital
Mnemo Therapeutics is a Paris-based clinical-stage biotech developing cell therapies using its EnfiniT epigenetic antigen discovery platform to target tumor-specific antigens for CAR-T therapies.
Co-investorsAlexandriaCasdin CapitalREDMILE
Provides pharmaceutical R&D services via the Cyto-Mine machine for single-cell analysis and characterisation.
Co-investors24 HaymarketQVenturesProvidence Investment Company LimitedREDMILE
Synthace provides a software platform for experimental design and lab automation, enabling researchers to run Design of Experiments (DOE) workflows across multiple automated laboratory instruments and devices.
AI & Machine LearningBiotechCloud ComputingDeep TechSaaS
Markus Gershater, PhD(Chief Executive Officer & Co-Founder)
Co-investors11.2 CapitalFuture Planet CapitalHorizons VenturesUK Innovation & Science Seed FundAmadeus Capital PartnersSOSV
TISSIUM develops biomorphic polymer technology, including proprietary polymers, activation technologies, and delivery devices, to reconstruct damaged tissue and restore its function across multiple therapeutic areas.
BiotechDeep TechMedical DevicesNew Materials
Christophe Bancel(Co-founder & CEO)inMaria Pereira(Co-inventor of the technology; leads the Innovation Hub)in
Co-investorsCapDecisif ManagementCathay HealthKaristaCathay InnovationEuropean Investment BankOmnes Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.